Fluoroquinolones Linked With Higher Risk Of Aortic Disease
The link between treatment with fluoroquinolone antibiotics and an increased risk of acute aortic disease gets added support via a new study from a Swedish and Danish team of researchers.
Fluoroquinolone antibiotics are used globally to treat a variety of infections. Recent observational studies have raised concerns that they may be associated with a more than twofold increase in the risk of acute and life-threatening aortic disease (aortic aneurysm or dissection). However, due to limitations in study design, it has not been possible to draw firm conclusions.
To assess whether there actually is a link, researchers from Karolinska Institutet and Lund University in Sweden and Statens Serum Institut in Denmark analysed data from Swedish national health registers. The researchers were then able to compare the risk of aortic aneurysm or dissection among more than 360,000 treatment episodes of fluoroquinolones with the risk among the same number of treatment episodes of amoxicillin, another type of antibiotic.
66 Per Cent Increased Risk
The results show a 66 per cent increase in the risk of aortic aneurysm or dissection in patients treated with fluoroquinolone antibiotics. This corresponded to an absolute difference of 82 cases per 1 million treatment courses with fluoroquinolone antibiotics.
“Our results confirm the findings in the previous studies but suggest that the increased risk is not as pronounced as indicated by those studies. Although the absolute risk increase was relatively small, the study’s findings should be interpreted in the context of the widespread use of fluoroquinolones. Our overall objective is to help inform clinical practice through high-quality evidence,”
Cumulative incidence of aortic aneurysm or dissection within 60 day risk period from start of study treatment. Credit: Pasternak Björn, Inghammar Malin, Svanström Henrik CC-BY
Like the previous ones, the current study is an observational study that is unable to prove a causal relationship. However, according to Björn Pasternak, because of its size and methodological design, it provides the most reliable results so far.
Activity Of Enzymes
The researchers also highlight a possible mechanism that might explain the association.
“One of the factors involved in the development of aortic disease is increased activity in tissue-degrading enzymes known as matrix metalloproteinases. We know that fluoroquinolones induce the activity of these enzymes, which is also thought to underlie the more well-known adverse effect of tendon pain and rupture”,
says Björn Pasternak.
The majority of treatment fluoroquinolone in the study were with ciprofloxacin; therefore the results are mainly applicable to that particular medication. Further research is needed to determine if there are differences between individual fluoroquinolones in terms of risk of aortic aneurysm.
Additional work is also needed to verify that the link is driven by aortic aneurysm, and not dissection, as well as the timing of onset of aortic aneurysm suggested by the study.